艾迪注射液联合5-氟尿嘧啶对原发性肝癌患者T淋巴细胞亚群的影响  

Effects of Aidi Injection Combined with 5-Fluorouracil on T Lymphocyte Subsets in Patients with Primary Hepatocellular Carcinoma

作　　者：侯传伟[1] 郑黎明[1] 赵雷[1] 孙庆春[1] 陈文生 王振奇 

机构地区：[1]吉化集团总医院,132022

出　　处：《实用癌症杂志》2017年第11期1851-1854,共4页The Practical Journal of Cancer

摘　　要：目的探究艾迪注射液联合化疗药物5-氟尿嘧啶对原发性肝癌患者T淋巴细胞亚群的作用。方法将86例原发性肝癌患者随机分成对照组和试验组,每组43例,对照组给予5-氟尿嘧啶进行化疗,试验组在对照组的基础上给予艾迪注射液(50 m L+5%葡萄糖500 m L)联合治疗,治疗30天后,比较两组的临床疗效、T淋巴细胞亚群(CD_3^+、CD_4^+、CD^+_(11c)、CD_4/CD_8)及血管内皮生长因子(VEGF)、细胞间黏附分子-1(ICAM-1)和甲胎蛋白(AFP)水平的差异,并对2组药物的安全性进行评价。结果试验组与对照组的总有效率分别为94.02%和79.07%,具有显著差异(P<0.01);治疗后试验组与对照组T淋巴细胞亚群CD_3^+含量分别为48.24±3.18和39.17±5.26,具有统计学差异(P<0.05);CD_4^+含量分别为40.82±5.61和25.32±2.68,具有显著差异(P<0.05);CD_(11c)含量分别为26.36±2.63和17.14±1.24,具有显著差异(P<0.05);VEGF含量为26.47±1.46和33.21±4.29,具有显著差异(P<0.05);ICAM-1含量为338.73±18.86和469.53±41.18,具有显著差异(P<0.01)。试验组不良反应如白细胞下降、骨髓抑制、腹泻及口腔溃疡等发生率均显著低于对照组。结论艾迪注射液联合5-氟尿嘧啶治疗原发性肝癌,能够有效提高临床效应,改善患者的生存质量,增加其免疫功能,降低药物不良反应。Objective To study the effect of Aidi injection combined with 5-fluorouracil on T lymphocyte subsets in patients with primary liver cancer. Methods 86 patients with primary hepatocellular carcinoma were randomly divided into the control group and the experimental group. The control group was treated with 5-fluorouracil for chemotherapy and the experimental group was given Aidi injection（50 mL ＋ 5% glucose 500 mL） based or/ the control group. After continuing treatment 30 days, compared the clinical efficacy, T lymphocyte subsets （ CD3± , CD4± , CD11c＋ , CD4/CD8 ）, vascular endothelial growth factor （ VEGF）, intercellular adhesion molecule-1 （ ICAM-1 ） and alpha-fetoprotein （ AFP）, safety evaluation of the 2 groups. Results The total effective rates of the .experimental group and the control group were 94.02% and 79.07% ,there had significant differ- ences （P 〈 0.01 ） ;the content levels of CD3± in the T lymphocyte subsets weie 48.24 ＋ 3.18 and 39.17± 5.26, there had sig- nificant differences ; the CD4＋ levels was 40.82 ± 5.61 and 25.32 ±2.68, there had significant differences ; the content of CDnc was 26.36± 2.63 and 17.14±1.24 ,there had significant differences, respectively;the content of VEGF was 26.47 ±1.46 and 33.21±4.29 with significant differences;The＇ content of ICAM-1 was 338.73±18.86 and 469.53± 41.18, there had significant differences. In the experimental group, the adverse effects of leukopenia, myelosuppression, diarrhea and oral ulcers were significantly lower than those of the control group. Conclusion Aidi injection combined with 5-fluorouracil for treating primary liver cancer,it can effectively improve the clinical effect,improve the quality of life of patients,increase their immune function and re- duce adverse drug reactions.

关 键 词：艾迪注射液 5-氟尿嘧啶 原发性肝癌 免疫功能 

分 类 号：R735.7[医药卫生—肿瘤]